Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy

Journal of Personalized Medicine, Journal Year: 2025, Volume and Issue: 15(2), P. 50 - 50

Published: Jan. 27, 2025

Drug resistance remains a significant barrier to effective cancer therapy. Cancer cells evade treatment by reprogramming their metabolism, switching from glycolysis oxidative phosphorylation (OXPHOS), and relying on alternative carbon sources such as glutamine. These adaptations not only enable tumor survival but also contribute immune evasion through mechanisms reactive oxygen species (ROS) generation the upregulation of checkpoint molecules like PD-L1. This review explores potential targeting metabolic weaknesses in drug-resistant cancers enhance therapeutic efficacy. Key pathways involved resistance, including glycolysis, glutamine kynurenine pathway, are discussed. The combination inhibitors with (ICIs), particularly anti-PD-1/PD-L1 therapies, represents promising approach overcoming both mechanisms. Clinical trials combining therapies have shown early promise, further research is needed optimize combinations identify biomarkers for patient selection. In conclusion, metabolism blockade offers novel drug providing pathway improved outcomes Future directions include personalized treatments based profiles expanding other types.

Language: Английский

SlNAC12, a novel NAC-type transcription factor, confers salt stress tolerance in tomato

Plant Cell Reports, Journal Year: 2024, Volume and Issue: 44(1)

Published: Dec. 14, 2024

Language: Английский